A Pilot Study on Edoxaban for the Resolution of Left Atrial Thrombosis in Patients With Non-valvular Atrial Fibrillation

NCT ID: NCT03489395

Last Updated: 2021-05-04

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 25 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-01-30
• Study Completion Date: 2021-04-30

Brief Summary

Isolated reports have indicated that complete Left Atrial or Left Atrial Appendage thrombus resolution may be achieved also with use of oral Factor Xa inhibitors, which have demonstrated the same efficacy but a better safety profile compared to warfarin.

The aim of this open-label pilot study is to investigate the percentage of Left Atrial /Left Atrial Appendage thrombus resolution with edoxaban therapy in patients with non-valvular atrial fibrillation. The subordinated aim is the design a larger and longer study to compare edoxaban and warfarin in the same patient population.

With the exception of few case reports, there are no data in the same patient population referred to antithrombotic treatments other than vitamin K antagonists.

Detailed Description

This is a non-controlled, open-label, 4 weeks pilot study.

As the main goal of this exploratory study is the estimation of the magnitude of the Left Atrial /Left Atrial Appendage thrombus resolution with edoxaban, no control group with vitamin K antagonists has been considered, providing that, for the purpose of this study, the magnitude of the response of warfarin is satisfactory defined.

Conditions

Atrial Fibrillation

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Edoxaban

Used for Treatment. All patients will receive edoxaban 60 mg once a day, with open-label design, for 4 weeks. Edoxaban daily dose will be reduced to 30 mg/day in case of: body weight ≤60 kg, or concomitant therapy with verapamil/quinidine/dronedarone.

Group Type: EXPERIMENTAL

Edoxaban

Intervention Type: DRUG

Edoxaban 60 mg once a day for 4 weeks. Edoxaban 30 mg/day in patients with body weight ≤60 kg, or with concomitant therapy with verapamil/quinidine/dronedarone.

Interventions

Edoxaban

Edoxaban 60 mg once a day for 4 weeks. Edoxaban 30 mg/day in patients with body weight ≤60 kg, or with concomitant therapy with verapamil/quinidine/dronedarone.

Intervention Type: DRUG

Other Intervention Names

Lixiana

Eligibility Criteria

Inclusion Criteria

Patients with all the following criteria will be eligible for inclusion in the study protocol:

1. Signed written informed consent.

2. Males and females ≥ 18 years of age.

3. Female subjects must be post-menopausal (for at least 2 years), surgically sterile, abstinent, or, if sexually active, be practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch, male partner sterilization) before entry and throughout the study; and, for those of childbearing potential, have a negative serum β-human chorionic gonadotropin pregnancy test at screening.

4. Atrial fibrillation (AF) must be documented by ECG evidence (e.g., 12-lead ECG, rhythm strip, Holter, pacemaker interrogation) within 30 days before enrolment.

5. Subjects with newly diagnosed atrial fibrillation are eligible provided that:

• -there is evidence that the atrial fibrillation is non-valvular:
• -there is ECG evidence on 2 occasions 24 hours apart demonstrating atrial fibrillation.

6. Left Atrial or Left Atrial Appendage thrombosis documented by trans-esophageal echocardiography (TEE)

7. Cardiac failure, Hypertension, Age (x2 ), Diabetes, Stroke (x 2) risk index-VASC score >1.

Exclusion Criteria

Patients with all the following criteria will not be eligible for inclusion in the study protocol:

1. Hemodynamically significant mitral valve stenosis.

2. Prosthetic heart mechanical or biological valve (annuloplasty with or without prosthetic ring, commissurotomy and/or valvuloplasty are permitted).

3. Transient atrial fibrillation caused by a reversible disorder (e.g., thyrotoxicosis, pulmonary embolism, recent surgery or myocardial infarction).

4. Known presence of atrial myxoma.

5. Left ventricular thrombus.

6. Active endocarditis.

7. Active internal bleeding.

8. History of condition associated with increased bleeding risk including, but not limited to:

• major surgical procedure or trauma within 30 days;
• clinically significant gastrointestinal bleeding within 6 months;
• previous intracranial, intraocular, spinal, atraumatic intra-articular bleeding;
• chronic haemorrhagic disorder;
• Any neoplasm, including intracranial neoplasm,
• arteriovenous malformation or aneurysm.

9. Platelet count <90,000/μL at the screening visit.

10. Sustained uncontrolled hypertension: Systolic Blood Pressure ≥180 mmHg or Diastolic Blood Pressure ≥100 mmHg.

11. Severe, disabling stroke (modified Rankin score of 4 to 5, inclusive within 3 months or any stroke < 14 days).

12. Transient ischemic attack within 3 days.

13. Any oral anticoagulant therapy at the time of the baseline visit.

14. Treatment with:

• aspirin >160 mg daily;
• aspirin plus a thienopyridine within 5 days;
• intravenous antiplatelets within 5 days;
• fibrinolytics within 10 days.

15. Anticipated need for therapy with a non-steroidal anti-inflammatory drug in the next 4 weeks.

16. Treatment with a strong inducer of cytochrome P450 and P glycoprotein, such as ketoconazole, itraconazole, voriconazole, posaconazole, ritonavir, lopinavir, telaprevir, indinavir, conivaptan, clarithromycin or planned treatment during the study.

17. Other indication for anticoagulant therapy.

18. Hypersensitivity or intolerance to the study drug, including excipients.

19. Women of childbearing potential who do not want adopt a contraceptive method during the study period and the following 4 weeks.

20. Breast-feeding women during the study period and the following 4 weeks.

21. Anemia (hemoglobin <10 g/dL) at the screening visit.

22. Known significant liver disease (e.g., acute clinical hepatitis, chronic active hepatitis, cirrhosis), or Alanine aminotransferase or Aspartate aminotransferase >2 x Upper Level of Normal or total bilirubin >1.5 x Upper Level of Normal.

23. Patients with moderate or severe renal impairment (CrCL <50 mL/min) or patients with end stage renal disease (CrCL < 15 mL/min) or on dialysis.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 99 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Hippocrates Research

OTHER

Sponsor Role: collaborator

Raffaele De Caterina

OTHER

Sponsor Role: lead

Responsible Party

Raffaele De Caterina

Professor

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Raffaele De Caterina

Role: PRINCIPAL_INVESTIGATOR

Università degli Studi G. d'Annunzio Chieti

Locations

Ospedale Madonna del Soccorso

San Benedetto del Tronto, Ascoli Piceno, Italy

Ospedale generale regionale "F. Miulli"

Acquaviva delle Fonti, Bari, Italy

Presidio Ospedaliero S. Maria delle Grazie

Pozzuoli, Napoli, Italy

AORN S.ANNA e S.SEBASTIANO

Caserta, , Italy

Università degli Studi G. D'Annunzio

Chieti, , Italy

Ospedale P. Monaldi

Napoli, , Italy

Policlinico AO di Padova

Padua, , Italy

Policlinico Universitario Campus Bio-Medico

Roma, , Italy

Countries

Italy

Provided Documents

Document Type: Study Protocol

View Document

Other Identifiers

2015-004847-37

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

EDO-SP-01-2015

Identifier Type: -

Identifier Source: org_study_id